MX2022014110A - Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario. - Google Patents
Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.Info
- Publication number
- MX2022014110A MX2022014110A MX2022014110A MX2022014110A MX2022014110A MX 2022014110 A MX2022014110 A MX 2022014110A MX 2022014110 A MX2022014110 A MX 2022014110A MX 2022014110 A MX2022014110 A MX 2022014110A MX 2022014110 A MX2022014110 A MX 2022014110A
- Authority
- MX
- Mexico
- Prior art keywords
- sting agonist
- immune checkpoint
- checkpoint inhibitors
- combination treatments
- patient
- Prior art date
Links
- 229940044665 STING agonist Drugs 0.000 title abstract 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 238000011284 combination treatment Methods 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción proporciona, entre otras cosas, métodos y usos para el tratamiento contra una enfermedad o trastorno, particularmente un cáncer en un paciente, que comprende la administración de manera conjunta de un inhibidor de CTLA4 (por ejemplo, un anticuerpo anti-CTLA4) y un agonista de STING al paciente, en donde el inhibidor de CTLA4 es administrable intratumoralmente al paciente. El agonista de STING puede ser administrable al paciente por vía intratumoral, oral o sistémica (por ejemplo, por vía intravenosa, intramuscular o subcutánea).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063025905P | 2020-05-15 | 2020-05-15 | |
US202063091874P | 2020-10-14 | 2020-10-14 | |
PCT/US2021/032800 WO2021232019A1 (en) | 2020-05-15 | 2021-05-17 | Sting agonist combination treatments with immune checkpoint inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014110A true MX2022014110A (es) | 2023-01-30 |
Family
ID=76306053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014110A MX2022014110A (es) | 2020-05-15 | 2021-05-17 | Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210380695A1 (es) |
EP (1) | EP4149457A1 (es) |
JP (1) | JP2023533111A (es) |
KR (1) | KR20230011324A (es) |
CN (1) | CN115803032A (es) |
AU (1) | AU2021273508A1 (es) |
CA (1) | CA3178464A1 (es) |
IL (1) | IL298148A (es) |
MX (1) | MX2022014110A (es) |
WO (1) | WO2021232019A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114940679B (zh) * | 2022-05-23 | 2023-05-16 | 浙江大学医学院附属第四医院 | Sting激动剂前药化合物及其制备方法和应用 |
WO2024064724A1 (en) * | 2022-09-21 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Compositions and methods for treating cancer |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014144666A2 (en) | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
TN2015000457A1 (en) | 2013-04-29 | 2017-04-06 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
PL3233882T3 (pl) | 2014-12-16 | 2020-04-30 | Kayla Therapeutics | Fluorowane cykliczne dinukleotydy do indukcji cytokin |
CA2977660A1 (en) * | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
UA123701C2 (uk) | 2015-08-13 | 2021-05-19 | Мерк Шарп І Доум Корп. | Циклічні динуклеотидні сполуки як агоністи sting |
DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
CA3017524A1 (en) | 2016-03-18 | 2017-09-21 | Immune Sensor, Llc | Cyclic di-nucleotide compounds and methods of use |
RU2019122598A (ru) | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные агонисты sting для лечения рака |
RU2019122602A (ru) | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака |
US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
US11638716B2 (en) | 2017-08-31 | 2023-05-02 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
JP7104999B2 (ja) | 2018-02-21 | 2022-07-22 | ザ スクリプス リサーチ インスティテュート | インターフェロン遺伝子刺激因子stingのアゴニスト |
WO2021076666A1 (en) * | 2019-10-14 | 2021-04-22 | Immunesensor Therapeutics, Inc. | Methods of treating cancer with a sting agonist |
-
2021
- 2021-05-17 CA CA3178464A patent/CA3178464A1/en active Pending
- 2021-05-17 CN CN202180046447.0A patent/CN115803032A/zh active Pending
- 2021-05-17 JP JP2022568780A patent/JP2023533111A/ja active Pending
- 2021-05-17 MX MX2022014110A patent/MX2022014110A/es unknown
- 2021-05-17 WO PCT/US2021/032800 patent/WO2021232019A1/en active Application Filing
- 2021-05-17 IL IL298148A patent/IL298148A/en unknown
- 2021-05-17 AU AU2021273508A patent/AU2021273508A1/en active Pending
- 2021-05-17 EP EP21730772.7A patent/EP4149457A1/en active Pending
- 2021-05-17 US US17/322,827 patent/US20210380695A1/en active Pending
- 2021-05-17 KR KR1020227042332A patent/KR20230011324A/ko active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
CN115803032A (zh) | 2023-03-14 |
WO2021232019A1 (en) | 2021-11-18 |
AU2021273508A1 (en) | 2022-12-15 |
CA3178464A1 (en) | 2021-11-18 |
IL298148A (en) | 2023-01-01 |
KR20230011324A (ko) | 2023-01-20 |
US20210380695A1 (en) | 2021-12-09 |
JP2023533111A (ja) | 2023-08-02 |
EP4149457A1 (en) | 2023-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014110A (es) | Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario. | |
Mercier | Fluid loading for cesarean delivery under spinal anesthesia: have we studied all the options? | |
Heizmann et al. | Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL | |
CR20190497A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
MX2021008267A (es) | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp. | |
PE20190205A1 (es) | Uso de inhibidores de miostatina y terapias de combinacion | |
MA43283B1 (fr) | Composition pour le traitement du cancer | |
MX2021006980A (es) | Anticuerpos anti-il-27 y usos de estos. | |
AR118720A1 (es) | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 | |
WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
WO2019202401A3 (en) | Immuno-oncolytic modified vaccinia tian tan virus and methods of treating cancer | |
PH12019501087A1 (en) | A pharmaceutical composition for averting opioid addiction | |
MX2021005801A (es) | Metodos para administrar corticosteroides. | |
MX2020009552A (es) | Composiciones para prevenir y/o tratar melanoma. | |
WO2020212514A8 (en) | Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer | |
Khalili et al. | Long acting propranolol and HSP-70 rich tumor lysate reduce tumor growth and enhance immune response against fibrosarcoma in Balb/c mice | |
Miao et al. | CD103+ Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model | |
MX2021006210A (es) | Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica. | |
AR115537A1 (es) | Terapia combinada con una vacuna neoantigénica | |
JOP20210247A1 (ar) | علاج الصداع باستخدام أجسام مضادة لـ cgrp | |
CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
MX2022014886A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. | |
MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
MX2022003686A (es) | Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial. | |
EA202191581A1 (ru) | Неотложное лечение и быстрое лечение головной боли с использованием антител к cgrp |